Target intelligence / Profile preview

Ras-related protein Rab-33B (RAB33B)

Target
RAB33B
Molecular classification
Small GTPase, Rab protein family, Vesicle transporter, Enzyme (GTPase), Intracellular trafficking regulator
01

Overview

Ras-related protein Rab-33B (RAB33B) is a small GTPase belonging to the Rab protein family, ubiquitously expressed in tissues. It orchestrates vesicle-mediated transport, primarily at the Golgi, regulating retrograde traffic from the Golgi to the endoplasmic reticulum and facilitating autophagosome formation by interacting with effectors such as Atg16L1. RAB33B plays a key role in Golgi homeostasis, endocytosis, and intracellular transport of proteins, and is crucial for cellular autophagy pathways. Mutations in RAB33B are causative for rare autosomal recessive skeletal dysplasia syndromes such as Smith-McCort and Dyggve-Melchior-Clausen. Recent research indicates that RAB33B is also exploited by influenza viruses to transport viral proteins to the plasma membrane through autophagy-based vesicles. No approved drugs target RAB33B directly, but its interaction with autophagy and vesicular machinery makes it a potential target for future therapeutic interventions, especially relevant in infections and possibly other trafficking-related disorders.

Other names
RAB33BRas-related protein Rab-33BDKFZP434G099SMC2Rab-33B
02

Mechanism of action

Modulation of autophagy (inhibition or activation alters RAB33B interactions and trafficking); Drugs affecting vesicle trafficking or Golgi function may indirectly influence RAB33B function

03

Biological functions

Vesicle-mediated transportGolgi to endoplasmic reticulum retrograde traffickingAutophagosome formationRegulation of protein secretion and endocytosisGolgi homeostasisModulator of autophagy
04

Disease associations

Skeletal dysplasias (Dyggve-Melchior-Clausen syndrome, Smith-McCort dysplasia)Viral infection facilitation (Influenza A viral replication)Potential implications in other intracellular trafficking-related diseasesCell migration/focal adhesion turnover
05

Safety considerations

Genetic mutations can cause severe skeletal and developmental disordersTargeting vesicular trafficking proteins may raise concerns about global effects on essential cell functions (autophagy, secretion, Golgi function)Disruption may affect protein homeostasis and immunity
06

Interacting drugs

No clinically approved drugs specifically target RAB33B as of now

1 more in the full profile.

07

Biomarkers

No established clinical biomarkers for RAB33BGenetic testing for mutations in RAB33B is used to diagnose associated skeletal dysplasias (Smith-McCort, Dyggve-Melchior-Clausen)

Beyond the preview

Go deeper on Ras-related protein Rab-33B (RAB33B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras-related protein Rab-33B (RAB33B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call